facebook facebook   ？ facebook ？？：？，。english us한국어français francebahasa indonesiapolskiespañolportuguês brasildeutschitalianomessengerfacebook liteinstagramcookie facebook   albireo expands team appoints martha j carter as chief regulatory officer  marketwatch bulletin investor alert press release nov    am est albireo expands team appoints martha j carter as chief regulatory officer boston nov   globe newswire via comtex  albireo pharma inc quoteszigmancomposite albo   a clinicalstage orphan pediatric liver disease company developing novel bile acid modulators today announced the appointment of martha j muffy carter as chief regulatory officer in this role ms carter will oversee all regulatory affairs for albireo worldwide the wealth of regulatory and operational experience muffy has accumulated during her four decades in the biopharmaceutical industry including having successfully secured approval for an orphan drug in  countries will be invaluable to albireo said ron cooper president and chief executive officer of albireo muffy will be instrumental in guiding a our lead product candidate in development for the treatment of progressive familial intrahepatic cholestasis pfic through the regulatory processes in the united states and europe we are delighted to welcome her to our management team most recently ms carter was chief regulatory officer and senior vice president of aegerion pharmaceuticals a biopharmaceutical company focused in rare diseases where she established global regulatory and quality functions and played a key role in bringing juxtapidrlojuxtar lomitapide for the treatment of homozygous familial hypercholesterolemia to market prior to aegerion ms carter served as senior vice president and chief regulatory officer at proteon therapeutics and senior vice president regulatory affairs at trine pharmaceuticals earlier in her career ms carter held various positions of increasing responsibility in regulatory affairs strategic planning and compliance she has authored and coauthored numerous publications on regulatory matters and professional ethics ms carter holds a ba in biology from northeastern university i am thrilled to be joining albireo as we ready a for a potentially pivotal clinical trial in pfic said ms carter i look forward to supporting the development of a and albireos pipeline of bile acid modulators as we work to bring much needed new treatment options to patients suffering from orphan liver diseases and gastrointestinal disorders about albireo albireo pharma is a clinicalstage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders albireos clinical pipeline includes two phase  product candidates and one phase  product candidate albireo was spun out from astrazeneca in  albireo pharma is located in boston massachusetts and its key operating subsidiary is located in gothenburg sweden for more information on albireo please visit wwwalbireopharmacom  forwardlooking statements  albireo this press release includes forwardlooking statements  forwardlooking statements include statements other than statements of historical fact regarding albireos intentions plans beliefs expectations or forecasts for the future including regarding a potentially pivotal clinical trial of a in pfic or the ability of albireo to successfully develop a or any of its pipeline product candidates and obtain regulatory approval albireo uses words such as anticipates believes plans expects projects future intends may will should could estimates predicts potential planned continue guidance and similar expressions to identify forwardlooking statements actual results performance or experience may differ materially from those expressed or implied by any forwardlooking statement as a result of various risks and uncertainties including but not limited to those described in the documents albireo fka biodel inc has filed with the securities and exchange commission risks and uncertainties relating to the conduct and results of albireos ongoing clinical trial of a in children with chronic cholestasis whether such ongoing clinical trial of a will be sufficient to support advancement of a into a pivotal clinical trial in pfic and the timing and success of submission acceptance and approval of regulatory filings as a result of risks and uncertainties that albireo faces the results or events indicated by any forwardlooking statement may not occur albireo cautions you not to place undue reliance on any forwardlooking statement in addition any forwardlooking statement in this press release represents albireos views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date albireo disclaims any obligation to update any forwardlooking statement except as required by applicable law source albireo pharma inc investor contact hans vitzthum lifesci advisors llc  media contact heather anderson  degrees  handersondegreesprcom copyright c  globenewswire inc all rights reserved quoteszigmancomposite add to watchlist albo albireo pharma inc us  us nasdaq     volume  july   p pe rationa dividend yieldna market cap million rev per employee most popular  the dark side of cruises  the reason jack bogle doesn’t fly first class says everything about his investing legacy  oj simpson made over  while in prison and won’t have to give any of it to the goldman family  if you’re reading this you have a  chance of being rich   luxury pool floats to class up your instagram find a broker partner center » featured stories seeing america again through new eyes how to dig yourself out of debt move over tesla karma unveils its hybrid sports car the salary you need to afford a home in these  cities why opec will never cut production again log in  am edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pcharges dropped after ‘london whale’ accused jamie dimon of making him a fall guy pgoodbye sean spicer memorable moments from the podium phow to fix wall street and bankers pay pamazon whole foods look to head off lengthy deal review phawaii adopts emergency plan for north korea missile attack p california wildfire destroys homes near yosemite pspicer quits as scaramucci accepts white house job pwhy you shouldn’t order ice on a flight and other ‘dirty little secrets’ pif you’re reading this you have a  chance of being rich p unfortunate reasons why millennials can’t have nice things or save any money pthis is the deadliest time of your life to put on weight pif like sean spicer you suddenly walk out — what should you do next pa history of sears through highs and lows pare you a money bully phow realestate tv shows determine what home buyers look for and what to do if you decide to quit your job like sean spicer pbreakingwall streets fear gaugethe vixjust logged its secondlowest close in history pwhy it might be time to invest in the companies amazon is destroying pthis is what should really worry you about stocks pbeware of the curse of the number  in the stock market psp  nasdaq post weekly gains as stock market finishes session lower loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  albireo news martha j carter joined as chief regulatory officer sign in  sign in  you need to sign in to access your  sign in sign in with your email address sign in via linkedin instead  we no longer support sign in via facebook or twitter please use your email instead thanks we sent you a link to sign in please check your inbox shortly ok if you dont receive the email please be sure to check your spam folder questions youll need to register to do that register with facebook creds register with linkedin creds register with google creds new registration registering will allow you to sync up the companies you are following with your phone  desktop and allow you to update company data and take surveys on owlercom sign up enter your business email domain is not valid please use a valid email address email address   we have sent an email to   containing an activation link please follow the link to complete your registration if you dont see it immediately check your spam folder ok resend thanks for registering please note you have been assigned change above if desired as a screen name you must confirm your email address to access all features of owler thank you for registering please note you have been assigned change above if desired as a screen name owler needs your email address we have resent an email to   containing an activation link please follow the link to complete your registration if you dont see it immediately check your spam folder your account has been locked please contact supportowlercom if you feel this is an error thanks just two more things  weve assigned you a random screen name please change as desired  please change your random password albireo expands team appoints martha j carter as chief regulatory officer  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street albireo expands team appoints martha j carter as chief regulatory officer globenewswire nov    am est boston nov   globe newswire  albireo pharma inc nasdaqalbo a clinicalstage orphan pediatric liver disease company developing novel bile acid modulators today announced the appointment of martha j muffy carter as chief regulatory officer in this role ms carter will oversee all regulatory affairs for albireo worldwide the wealth of regulatory and operational experience muffy has accumulated during her four decades in the biopharmaceutical industry including having successfully secured approval for an orphan drug in  countries will be invaluable to albireo said ron cooper president and chief executive officer of albireo muffy will be instrumental in guiding a our lead product candidate in development for the treatment of progressive familial intrahepatic cholestasis pfic through the regulatory processes in the united states and europe we are delighted to welcome her to our management team most recently ms carter was chief regulatory officer and senior vice president of aegerion pharmaceuticals a biopharmaceutical company focused in rare diseases where she established global regulatory and quality functions and played a key role in bringing juxtapid®lojuxta® lomitapide for the treatment of homozygous familial hypercholesterolemia to market prior to aegerion ms carter served as senior vice president and chief regulatory officer at proteon therapeutics and senior vice president regulatory affairs at trine pharmaceuticals earlier in her career ms carter held various positions of increasing responsibility in regulatory affairs strategic planning and compliance she has authored and coauthored numerous publications on regulatory matters and professional ethics ms carter holds a ba in biology from northeastern university i am thrilled to be joining albireo as we ready a for a potentially pivotal clinical trial in pfic said ms carter i look forward to supporting the development of a and albireos pipeline of bile acid modulators as we work to bring much needed new treatment options to patients suffering from orphan liver diseases and gastrointestinal disorders trending amazon deceptive pricing probe by the ftc could be the start of a government siege sears just surrendered to amazon with kenmore deal dont sleep on general electrics cheap stock price chipotles new health scare could trigger a hindenburg scenario expert says bored with cream and sugar you can now add weed to your morning joe advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers       albireo expands team appoints martha j carter as chief regulatory officer employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       albireo albo expands team appoints martha j carter as chief regulatory officer tweet   am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs boston nov   globe newswire  albireo pharma inc nasdaqalbo a clinicalstage orphan pediatric liver disease company developing novel bile acid modulators today announced the appointment of martha j muffy carter as chief regulatory officer in this role ms carter will oversee all regulatory affairs for albireo worldwide “the wealth of regulatory and operational experience muffy has accumulated during her four decades in the biopharmaceutical industry including having successfully secured approval for an orphan drug in  countries will be invaluable to albireo” said ron cooper president and chief executive officer of albireo “muffy will be instrumental in guiding a our lead product candidate in development for the treatment of progressive familial intrahepatic cholestasis pfic through the regulatory processes in the united states and europe we are delighted to welcome her to our management team” most recently ms carter was chief regulatory officer and senior vice president of aegerion pharmaceuticals a biopharmaceutical company focused in rare diseases where she established global regulatory and quality functions and played a key role in bringing juxtapid®lojuxta® lomitapide for the treatment of homozygous familial hypercholesterolemia to market prior to aegerion ms carter served as senior vice president and chief regulatory officer at proteon therapeutics and senior vice president regulatory affairs at trine pharmaceuticals earlier in her career ms carter held various positions of increasing responsibility in regulatory affairs strategic planning and compliance she has authored and coauthored numerous publications on regulatory matters and professional ethics ms carter holds a ba in biology from northeastern university “i am thrilled to be joining albireo as we ready a for a potentially pivotal clinical trial in pfic” said ms carter “i look forward to supporting the development of a and albireo’s pipeline of bile acid modulators as we work to bring much needed new treatment options to patients suffering from orphan liver diseases and gastrointestinal disorders” about albireoalbireo pharma is a clinicalstage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders albireo’s clinical pipeline includes two phase  product candidates and one phase  product candidate albireo was spun out from astrazeneca in  albireo pharma is located in boston massachusetts and its key operating subsidiary is located in gothenburg sweden for more information on albireo please visit wwwalbireopharmacom forwardlooking statements — albireothis press release includes “forwardlooking statements”  forwardlooking statements include statements other than statements of historical fact regarding albireo’s intentions plans beliefs expectations or forecasts for the future including regarding a potentially pivotal clinical trial of a in pfic or the ability of albireo to successfully develop a or any of its pipeline product candidates and obtain regulatory approval albireo uses words such as “anticipates” “believes” “plans” “expects” “projects” “future” “intends” “may” “will” “should” “could” “estimates” “predicts” “potential” “planned” “continue” “guidance” and similar expressions to identify forwardlooking statements actual results performance or experience may differ materially from those expressed or implied by any forwardlooking statement as a result of various risks and uncertainties including but not limited to those described in the documents albireo fka biodel inc has filed with the securities and exchange commission risks and uncertainties relating to the conduct and results of albireo’s ongoing clinical trial of a in children with chronic cholestasis whether such ongoing clinical trial of a will be sufficient to support advancement of a into a pivotal clinical trial in pfic and the timing and success of submission acceptance and approval of regulatory filings as a result of risks and uncertainties that albireo faces the results or events indicated by any forwardlooking statement may not occur albireo cautions you not to place undue reliance on any forwardlooking statement in addition any forwardlooking statement in this press release represents albireo’s views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date albireo disclaims any obligation to update any forwardlooking statement except as required by applicable law source albireo pharma inc investor contact hans vitzthum lifesci advisors llc  media contact heather anderson  degrees  handersondegreesprcom read at biospacecom related news how boston biotech albireo albo goes public in unusual fashion presidentelect trump set to debut dream team for healthcare reform albireo albo’s lead product candidate for orphan pediatric liver disease accepted into emas prime program french cancer specialist innate pharma iphpa  can remain independent for now ceo albireo albo completes transaction with biodel biod to create publicly traded company focused on orphan pediatric liver diseases trump names rep tom price as next hhs secretary bostons albireo reports positive late stage data results for elobixibat how donald trump could disrupt the fda bostons albireo taps alexion alxn exec as new cmo retired former novartis ag nvs rd cancer head returns for a new gig at the danafarber cancer institute please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • albireo   • biotechpharma  personnel                 albireo expands team appoints martha j carter as chief regulatory officer nasdaqalbo facebook google linkedin twitter email rss nov   previous release  next release pdf add to briefcase file is in briefcase albireo expands team appoints martha j carter as chief regulatory officer boston nov   globe newswire  albireo pharma inc nasdaqalbo a clinicalstage orphan pediatric liver disease company developing novel bile acid modulators today announced the appointment of martha j muffy carter as chief regulatory officer in this role ms carter will oversee all regulatory affairs for albireo worldwide the wealth of regulatory and operational experience muffy has accumulated during her four decades in the biopharmaceutical industry including having successfully secured approval for an orphan drug in  countries will be invaluable to albireo said ron cooper president and chief executive officer of albireo muffy will be instrumental in guiding a our lead product candidate in development for the treatment of progressive familial intrahepatic cholestasis pfic through the regulatory processes in the united states and europe we are delighted to welcome her to our management team most recently ms carter was chief regulatory officer and senior vice president of aegerion pharmaceuticals a biopharmaceutical company focused in rare diseases where she established global regulatory and quality functions and played a key role in bringing juxtapid®lojuxta® lomitapide for the treatment of homozygous familial hypercholesterolemia to market prior to aegerion ms carter served as senior vice president and chief regulatory officer at proteon therapeutics and senior vice president regulatory affairs at trine pharmaceuticals earlier in her career ms carter held various positions of increasing responsibility in regulatory affairs strategic planning and compliance she has authored and coauthored numerous publications on regulatory matters and professional ethics ms carter holds a ba in biology from northeastern university i am thrilled to be joining albireo as we ready a for a potentially pivotal clinical trial in pfic said ms carter i look forward to supporting the development of a and albireos pipeline of bile acid modulators as we work to bring much needed new treatment options to patients suffering from orphan liver diseases and gastrointestinal disorders about albireoalbireo pharma is a clinicalstage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders albireos clinical pipeline includes two phase  product candidates and one phase  product candidate albireo was spun out from astrazeneca in  albireo pharma is located in boston massachusetts and its key operating subsidiary is located in gothenburg sweden for more information on albireo please visit wwwalbireopharmacom forwardlooking statements — albireothis press release includes forwardlooking statements  forwardlooking statements include statements other than statements of historical fact regarding albireos intentions plans beliefs expectations or forecasts for the future including regarding a potentially pivotal clinical trial of a in pfic or the ability of albireo to successfully develop a or any of its pipeline product candidates and obtain regulatory approval albireo uses words such as anticipates believes plans expects projects future intends may will should could estimates predicts potential planned continue guidance and similar expressions to identify forwardlooking statements actual results performance or experience may differ materially from those expressed or implied by any forwardlooking statement as a result of various risks and uncertainties including but not limited to those described in the documents albireo fka biodel inc has filed with the securities and exchange commission risks and uncertainties relating to the conduct and results of albireos ongoing clinical trial of a in children with chronic cholestasis whether such ongoing clinical trial of a will be sufficient to support advancement of a into a pivotal clinical trial in pfic and the timing and success of submission acceptance and approval of regulatory filings as a result of risks and uncertainties that albireo faces the results or events indicated by any forwardlooking statement may not occur albireo cautions you not to place undue reliance on any forwardlooking statement in addition any forwardlooking statement in this press release represents albireos views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date albireo disclaims any obligation to update any forwardlooking statement except as required by applicable law source albireo pharma inc investor contact hans vitzthum lifesci advisors llc  media contact heather anderson  degrees  handersondegreesprcom source albireo inc news provided by acquire media home site map about us media kit contact us help register now why register login  the leading web portal for pharmacy resources news education and careers july   news drug delivery systems drugstores fda final approvals front page healthcare news generic drugs hospital industry internet pharmacy it in healthcare medicare  medicaid overthecounter drugs pharm industry trends and policy pharmaceutical development pharmaceutical industry pharmacy careers pharmacist pharmacy technician pharmacy job board job placement help so you want a job as a pharmacist start your career as apharmacy technician resources boards of pharmacy drug database fda resources pharmacy associations pharmacy journals pharmacy newsletters state associations more education certification courses continuing education disease state management international pharmacy schools live online ce pharmacy schools pharmacy technician training business advertising information  media kit consulting contact us pharmacy marketing marketplace drug manufacturers drug wholesalers automation and robotics compounding supplies medication  supply dispensing systems tablet  capsule counters wholesalers  distributors more pharmacy choice  pharmaceutical news  albireo expands team appoints martha j carter as chief regulatory officer  july   pharmacy news article    albireo expands team appoints martha j carter as chief regulatory officer boston nov   globe newswire albireo pharma inc nasdaqalbo a clinicalstage orphan pediatric liver disease company developing novel bile acid modulators today announced the appointment of martha j muffy carter as chief regulatory officer in this role ms carter will oversee all regulatory affairs for albireo worldwide the wealth of regulatory and operational experience muffy has accumulated during her four decades in the biopharmaceutical industry including having successfully secured approval for an orphan drug in  countries will be invaluable to albireo said ron cooper president and chief executive officer of albireo muffy will be instrumental in guiding a our lead product candidate in development for the treatment of progressive familial intrahepatic cholestasis pfic through the regulatory processes in the united states and europe we are delighted to welcome her to our management team most recently ms carter was chief regulatory officer and senior vice president of aegerion pharmaceuticals a biopharmaceutical company focused in rare diseases where she established global regulatory and quality functions and played a key role in bringing juxtapidlojuxta lomitapide for the treatment of homozygous familial hypercholesterolemia to market prior to aegerion ms carter served as senior vice president and chief regulatory officer at proteon therapeutics and senior vice president regulatory affairs at trine pharmaceuticals earlier in her career ms carter held various positions of increasing responsibility in regulatory affairs strategic planning and compliance she has authored and coauthored numerous publications on regulatory matters and professional ethics ms carter holds a ba in biology from northeastern university i am thrilled to be joining albireo as we ready a for a potentially pivotal clinical trial in pfic said ms carter i look forward to supporting the development of a and albireos pipeline of bile acid modulators as we work to bring much needed new treatment options to patients suffering from orphan liver diseases and gastrointestinal disorders about albireoalbireo pharma is a clinicalstage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders albireos clinical pipeline includes two phase  product candidates and one phase  product candidate albireo was spun out from astrazeneca in  albireo pharma is located in boston massachusetts and its key operating subsidiary is located in gothenburg sweden for more information on albireo please visit wwwalbireopharmacom forwardlooking statements albireothis press release includes forwardlooking statements forwardlooking statements include statements other than statements of historical fact regarding albireos intentions plans beliefs expectations or forecasts for the future including regarding a potentially pivotal clinical trial of a in pfic or the ability of albireo to successfully develop a or any of its pipeline product candidates and obtain regulatory approval albireo uses words such as anticipates believes plans expects projects future intends may will should could estimates predicts potential planned continue guidance and similar expressions to identify forwardlooking statements actual results performance or experience may differ materially from those expressed or implied by any forwardlooking statement as a result of various risks and uncertainties including but not limited to those described in the documents albireo fka biodel inc has filed with the securities and exchange commission risks and uncertainties relating to the conduct and results of albireos ongoing clinical trial of a in children with chronic cholestasis whether such ongoing clinical trial of a will be sufficient to support advancement of a into a pivotal clinical trial in pfic and the timing and success of submission acceptance and approval of regulatory filings as a result of risks and uncertainties that albireo faces the results or events indicated by any forwardlooking statement may not occur albireo cautions you not to place undue reliance on any forwardlooking statement in addition any forwardlooking statement in this press release represents albireos views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date albireo disclaims any obligation to update any forwardlooking statement except as required by applicable law source albireo pharma inc investor contact hans vitzthum lifesci advisors llc  media contact heather anderson  degrees  handersondegreesprcom source albireo inc  globenewswire inc pharmacy news index   drug delivery systems   drugstores   fda final approvals   front page healthcare news   generic drugs   hospital industry   internet pharmacy   it in healthcare   medicare  medicaid   overthecounter drugs   pharm industry trends and policy   pharmaceutical development   pharmaceutical industry live online ce jul  rems drugs  the practice of pharmacy a program in law and risk management jul  whats new new treatments for type  diabetes jul  management of schizophrenia  acute agitation jul  on the move a comprehensive review of osteoarthritis gout  rheumatoid arthritis jul  obesity management overview of pharmacotherapy click for entire webinar calendar special announcement free membership enjoy drug search industry newsletters and more nursing jobs are you a nurse looking for a job check out the nursing job source your number one choice for nursing jobs websites » rxcareercentercom • rxschoolcom • clubstaffingcom • nursingjobsourcecom • rncom news drug delivery systems drugstores fda final approvals front page healthcare news generic drugs hospital industry internet pharmacy it in healthcare medicare  medicaid overthecounter drugs pharm industry trends and policy pharmaceutical development pharmaceutical industry careers pharmacist pharmacy technician pharmacy job board jobs placement help so you want a job as a pharmacist start your career as apharmacy technician resources boards of pharmacy drug databases fda resources pharmacy associations pharmacy journals pharmacy newsletters state associations more education certification courses continuing education disease state management international pharmacy schools live online ce pharmacy ce pharmacy schools pharmacy tech training business advertising information consulting contact us pharmacy marketing marketplace drug manufacturers drug wholesalers automation and robotics compounding supplies medication  supply   dispensing systems tablet  capsule counters wholesalers  distributors more most popular pharmacy jobs continuing education fda resources drug information pharmacy news disease states pharm tech training copyright   pharmacy choice  all rights reserved terms and conditions  privacy statement  carters martha toddlerlittle kid at pmcom free shipping any  items or  see details  am  pm pst log inlogout my account close  am  pm pst shoes womens sandals sneakers flats heels clogs  mules view all mens sneakers sandals boat shoes loafers oxfords view all the sandals shop the luxury shop summer shoe trends clothing womens dresses shirts  tops swimwear shorts view all mens shirts  tops shorts swimwear pants view all specialty shops juniors shop swim shop athletic shop outdoor shop luxury shop plus size shop bags all bags handbags backpacks wallets  accessories luggage view all top styles cross body totes shoulder bags satchels clutches top brands coach tommy hilfiger valentino bags by mario valentino steve madden frye accessories all accessories sunglasses hats watches jewelry belts sunglass styles aviators oval rectangular cat eye view all top brands oakley spy optic under armour guess columbia womens shoes sandals sneakers flats heels view all clothing dresses shirts  tops activewear swimwear view all handbags eyewear watches jewelry accessories specialty sizes plus size petite juniors mens shoes sneakers sandals boat shoes loafers view all clothing shirts  tops shorts activewear swimwear view all bags eyewear accessories kids boys shoes clothing accessories view all girls shoes clothing accessories view all shop by age infant toddler little kid big kid clearance brands featured brands coach brooks nine west asics nike ugg oakley skechers cole haan brand index  a b c d e f g h i j k l m n o p q r s t u v w x y z need help up to  off msrp shop now back   shoes sneakers  athletic shoes carters carters martha toddlerlittle kid product information sku  stay golden pony girl textile upper laceup closure stitch detail soft fabric lining and footbed rubber outsole imported measurements weight  oz product measurements were taken using size  toddler width m please note that measurements may vary by size msrp   color gold size size chart select a size  toddler  toddler  toddler  little kid  little kid width m add to shopping bag add to favorites share tweet pin it email shop with confidence shopping on pmcom is safe safe shopping guarantee shipping free shipping when you buy  or more items or  item over  see details return policy pmcom will be happy to accept a return within  days of the date of purchase learn more customer service safe shopping guarantee forgot password shipping rates return policy faqs contact info shopping womens mens kids brands my account loginregister my account order status order history print an invoice track my order information about site map coupons find us on resources associates program how do you like our website wed like to get your feedback terms of use privacy policy interestbased ads welg   zapposcom inc or its affiliates  east stewart avenue las vegas nv  pmcom is operated by zappos ip inc products on pmcom are sold by pmcom llc egift cards on pmcom are sold by aci gift cards inc for premier service selection and shipping visit zapposcom — your onestop shop for the latest in shoes sandals dresses jeans and more for luxury and designer styles visit zappos luxury  forbidden forbidden you dont have permission to access productcartersmarthagirlsinfanttoddler on this server apache server at wwwmasseyscom port